The use of SGLT2 inhibitors is now recommended as part of treatment protocols based on international guidelines, including the Kidney Disease: Improving Global Outcomes (KDIGO) 2022, which advise their administration for patients with T2DM and CKD, regardless of glycemic control [26]. The gene discussed is SLC5A2; the disease is chronic kidney disease.